Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Biovail/Elan FTC Settlement: Elan Generic Adalat To Switch Distributors

  • News

Executive Summary

Elan plans to launch its generic version of Bayer's Adalat CC through a new distributor following a settlement with the Federal Trade Commission

You may also be interested in...



Elan generic Adalat distributor

Watson will distribute Elan's 30 mg and 60 mg versions of Bayer's Adalat CC under licensing agreement. A Federal Trade Commission settlement terminated the licensing deal between Biovail and Elan for extended-release nifedipine (1"The Pink Sheet" July 1, p. 8)...

Elan generic Adalat distributor

Watson will distribute Elan's 30 mg and 60 mg versions of Bayer's Adalat CC under licensing agreement. A Federal Trade Commission settlement terminated the licensing deal between Biovail and Elan for extended-release nifedipine (1"The Pink Sheet" July 1, p. 8)...

Biovail Generic Adalat May Be Sublicensed Under Pending FTC Settlement

Biovail may sublicense Elan's generic version of Bayer's Adalat CC under a pending settlement with the Federal Trade Commission

Table

View full table

Tags:
Latest Headlines

Lack Of Industry Involvement In Scoping Process Exacerbates ‘Unworkable’ Timelines

CDER, CBER Not Seeing Hiring Slowdown Despite US FDA Warnings

Medicare Reimbursement For Part B Drugs Is 48% Above 340B Prices To Hospitals, MedPAC Finds

Drug Shortages, Inspections In Focus At US FDA Appropriations Hearing

See All
UsernamePublicRestriction

Register

PS040068

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By